AstraZeneca Upbeat On China Prospects For New Products
China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.
You may also be interested in...
Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.
The China FDA’s new priority reviews and faster approval procedures for innovative drugs are beginning to bear fruit, with multinationals and patients among the first beneficiaries from recent clearances from two novel cancer drugs in this large emerging market.
Multinational pharma firms have had a widely varied quarter in China, with some clear winners emerging with double-digit growth while others are still in the doldrums. What are the factors behind the figures?